Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society

Mara Dierssen, Yann Herault, Pablo Helguera, Maria Martinez de Lagran, Anna Vazquez, Bradley Christian, Maria Carmona-Iragui, Frances Wiseman, William Mobley, Elizabeth M. C. Fisher, Veronique Brault, Anna Esbensen, Lisa M. Jacola, Marie Claude Potier, Eric D. Hamlett, Leonard Abbeduto, Laura del Hoyo Soriano, Jorge Busciglio, Maria Florencia Iulita, John CrispinoSebastien Malinge, Eugenio Barone, Marzia Perluigi, Floriana Costanzo, Jean Maurice Delabar, Renata Bartesaghi, Alain D. Dekker, Peter De Deyn, Juan Fortea Ormaechea, Patricia A. Shaw, Tarik F. Haydar, Stephanie L. Sherman, Andre Strydom, Anita Bhattacharyya*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.

Original languageEnglish
Pages (from-to)1-17
Number of pages17
JournalMolecular Syndromology
Early online date20-May-2021
DOIs
Publication statusPublished - 20-May-2021

Keywords

  • Down syndrome
  • Intellectual disability
  • Language impairment
  • Mouse models
  • Neurodevelopmental disorders
  • Alzheimer&#8217
  • s disease
  • Biomarkers
  • Trisomy 21 Research Society
  • ALZHEIMERS-DISEASE
  • GENE DOSAGE
  • ADULTS
  • DYSFUNCTION
  • BIOMARKER

Cite this